[ET Net News Agency, 14 November 2019] 3SBio Inc. (01530) said the clinical trial
application of the group's HIF-117 Capsule (SSS17) has been approved by the National
Medical Products Administration on 12 November 2019. The group is currently actively
preparing for initiating the clinical trial of such product.
HIF-117 Capsule is a selective small molecule inhibitor to hypoxia inducible factor
proline hydroxylase (HIF-PH). (RC)